S'abonner

Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients - 16/05/19

Doi : 10.1016/j.jaad.2018.12.053 
Chuandi Zhou, MD, PhD a, b, Fan Wu, MD a, b, Peiwei Chai, MD, PhD a, b, Yingyun Shi, MD a, b, Juan Ye, MD, PhD c, Xin Shi, MD, PhD c, Jia Tan, MD, PhD d, Yi Ding, MD, PhD a, b, Yingxiu Luo, MD a, b, Bita Esmaeli, MD, PhD e, Renbing Jia, MD, PhD a, b, , Xianqun Fan, MD, PhD a, b,
a Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China 
b Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China 
c Department of Ophthalmology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China 
d Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China 
e Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 

Reprint requests: Xianqun Fan, MD, PhD, Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No 639 Zhi Zao Ju Road, Shanghai 200011, China.Department of OphthalmologyNinth People's HospitalShanghai Jiao Tong University School of MedicineNo 639 Zhi Zao Ju RoadShanghai200011China∗∗Correspondence to: Renbing Jia MD, PhD, Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No 639 Zhi Zao Ju Road, Shanghai 200011, China.Department of OphthalmologyNinth People's HospitalShanghai Jiao Tong University School of MedicineNo 639 Zhi Zao Ju RoadShanghai200011China

Abstract

Background

The decision to perform Mohs micrographic surgery (MMS) or wide local excision (WLE) for eyelid sebaceous carcinoma (SC) is controversial.

Objective

To compare local recurrence, metastasis, and tumor-related mortality of patients with eyelid SC who were initially treated with MMS versus with WLE.

Methods

A multicenter cohort study. Medical records were reviewed for factors associated with recurrence, metastasis, and tumor-related mortality. All eligible patients were followed up. The impact of initial surgical modality on the prognoses were determined by Cox analyses after control for all confounders.

Results

Of the 360 patients included in this cohort, 115 (31.9%) underwent MMS as primary resection, whereas 245 (68.1%) underwent WLE. After a median follow-up period of 60.0 months, local recurrence was observed in 18 patients (15.7%) in the MMS group and 97 patients (39.6%) in the WLE group. Metastasis occurred in 9 patients (7.8%) who underwent MMS and 38 (15.5%) who underwent WLE. In all, 6 patients in the MMS group (5.2%) and 21 in the WLE group (8.6%) died of metastatic SC. Multivariable Cox regression indicated that compared with the WLE group, the MMS group exhibited more favorable local recurrence control (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.24-0.73; P = .002) but a comparable metastasis rate (HR, 1.38; 95% CI, 0.60-3.18; P = .453) and comparable tumor-related mortality (HR, 1.70; 95% CI, 0.59-4.93; P = .329). However, this beneficial effect became nonremarkable for patients with pagetoid intraepithelial neoplasia (HR, 1.73; 95% CI, 0.37-8.21; P = .488).

Limitations

Retrospective nature of the study.

Conclusion

MMS should be proposed for eyelid SC without orbital involvement to achieve recurrence control; however, this surgical procedure did not change the long-term outcomes in terms of metastasis or tumor-related mortality. Patients with pagetoid intraepithelial neoplasia may require adjuvant measures.

Le texte complet de cet article est disponible en PDF.

Key words : eyelid sebaceous carcinoma, metastasis, Mohs micrographic surgery, recurrence, tumor-related mortality

Abbreviations used : CI, HR, MMS, SC, UM, WLE


Plan


 Chuandi Zhou and Fan Wu contributed equally to this paper.
 Funding sources: Supported by the Scientific Research Program of the National Health and Family Planning Commission of China (201402014), The Science and Technology Commission of Shanghai (17DZ2260100), Innovation Fund for Translational Medicine (15ZH1005), and Shanghai Shuguang Project (14SG18). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 Conflicts of interest: None disclosed.


© 2019  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 6

P. 1608 - juin 2019 Retour au numéro
Article précédent Article précédent
  • Incidence of pneumocystosis among patients exposed to immunosuppression
  • Sergey Rekhtman, Andrew Strunk, Amit Garg
| Article suivant Article suivant
  • Patients with negative patch tests: Retrospective analysis of North American Contact Dermatitis Group (NACDG) data 2001-2016
  • Erin M. Warshaw, Amy J. Zhang, Donald V. Belsito, Joseph F. Fowler, James S. Taylor, Howard I. Maibach, Toby Mathias, Denis Sasseville, James G. Marks, Vincent A. DeLeo, Anthony F. Fransway, Kathryn A. Zug, Melanie D. Pratt, Matthew J. Zirwas, Joel G. DeKoven

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.